Document is current

Any future updates will be listed below

Bei CLL hat Typ-II-Anti-CD20-Antikörper Vorteile

Crossref DOI link: https://doi.org/10.1007/s15015-015-2030-8

Published Online: 2015-09-16

Published Print: 2015-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark